BG98217A - Определяне на предшественици,метаболизиращи се вчерния дроб до биологично активни продукти и терапевтичното им приложение - Google Patents

Определяне на предшественици,метаболизиращи се вчерния дроб до биологично активни продукти и терапевтичното им приложение Download PDF

Info

Publication number
BG98217A
BG98217A BG98217A BG9821793A BG98217A BG 98217 A BG98217 A BG 98217A BG 98217 A BG98217 A BG 98217A BG 9821793 A BG9821793 A BG 9821793A BG 98217 A BG98217 A BG 98217A
Authority
BG
Bulgaria
Prior art keywords
precursor
liver
biologically active
active compound
compound
Prior art date
Application number
BG98217A
Other languages
Bulgarian (bg)
English (en)
Inventor
Yung-Chi Cheng
Chien-Neng Chang
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of BG98217A publication Critical patent/BG98217A/bg

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG98217A 1991-05-15 1993-11-12 Определяне на предшественици,метаболизиращи се вчерния дроб до биологично активни продукти и терапевтичното им приложение BG98217A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70146291A 1991-05-15 1991-05-15
US82947492A 1992-02-03 1992-02-03
PCT/US1992/004142 WO1992020816A1 (en) 1991-05-15 1992-05-15 Determination of prodrugs metabolizable by the liver and therapeutic use thereof

Publications (1)

Publication Number Publication Date
BG98217A true BG98217A (bg) 1995-02-28

Family

ID=27106792

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98217A BG98217A (bg) 1991-05-15 1993-11-12 Определяне на предшественици,метаболизиращи се вчерния дроб до биологично активни продукти и терапевтичното им приложение

Country Status (13)

Country Link
US (1) US5728684A (no)
EP (1) EP0586523A4 (no)
JP (1) JPH06507902A (no)
KR (1) KR100245252B1 (no)
AU (1) AU673803B2 (no)
BG (1) BG98217A (no)
CA (1) CA2103050A1 (no)
HU (1) HUT67392A (no)
IE (1) IE921581A1 (no)
IL (1) IL101879A (no)
NO (2) NO306850B1 (no)
RU (1) RU2126255C1 (no)
WO (1) WO1992020816A1 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9600847D0 (en) 1996-01-16 1996-03-20 Smithkline Beecham Plc Pharmaceuticals
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
WO2000013708A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
US6818227B1 (en) 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
EP1169322B8 (en) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
AU5922700A (en) * 1999-07-09 2001-01-30 Board Of Regents Of The University Of Nebraska, The Therapy, prevention of recurrence, and diagnosis of colorectal cancer with radiopharmaceuticals
AU5840200A (en) 1999-07-13 2001-01-30 Medicure Inc. Treatment of diabetes and related pathologies
EP1872797A3 (en) 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
WO2001064692A1 (en) 2000-02-29 2001-09-07 Medicure International Inc. Cardioprotective phosphonates and malonates
US6586414B2 (en) 2000-03-28 2003-07-01 Medicure International Inc. Treatment of cerebrovascular disease
ATE364595T1 (de) 2000-07-07 2007-07-15 Medicure Int Inc Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US8207142B2 (en) * 2001-07-31 2012-06-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
US7015022B2 (en) * 2002-06-07 2006-03-21 University Of Medicine & Dentistry Of New Jersey Mammalian catalase-dependent oxidation processes and methods for stimulating oxidative activities
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
JP2008505126A (ja) * 2004-07-07 2008-02-21 メディキュア インターナショナル インコーポレイテッド 血小板凝集薬を用いる併用療法
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
CA2585165A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CA2632090A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
EP2408306A4 (en) * 2009-03-20 2012-11-07 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
RU2527457C2 (ru) * 2012-09-27 2014-08-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Ингибиторы поли(адф-рибозо)полимеразы-1 человека на основе производных урацила
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
WO2016057699A1 (en) 2014-10-07 2016-04-14 Kinsella Timothy J METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH 5-IODO-2-PYRIMIDINONE-2'-DEOXYRIBOSE (IPdR)
CA3049251A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Inc. Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
CN118697876A (zh) * 2017-02-09 2024-09-27 完美日光有限公司 用于自闭症谱系障碍药物治疗的方法
EP4003508A1 (en) 2019-07-31 2022-06-01 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895937A (en) * 1982-01-05 1990-01-23 The Research Foundation Of State University Of New York 5-ioso-2-pyrimidinone nucleoside
US4468384A (en) * 1982-01-05 1984-08-28 The Research Foundation Of State University Of New York Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides
US4782142A (en) * 1982-01-05 1988-11-01 The Research Foundation Of State University Of New York Novel 5-substituted 2-pyrimidinone nucleosides and methods of use
AU601556B2 (en) * 1987-03-16 1990-09-13 Wellcome Foundation Limited, The Therapeutic nucleosides
US4942226A (en) * 1988-12-29 1990-07-17 Merck & Co., Inc. Halogenated pyrimidine nucleosides and their derivatives
ES2111569T3 (es) * 1990-07-19 1998-03-16 Wellcome Found Inactivadores de enzimas.
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations

Also Published As

Publication number Publication date
WO1992020816A1 (en) 1992-11-26
NO934059L (no) 1993-12-30
RU2126255C1 (ru) 1999-02-20
HUT67392A (en) 1995-04-28
CA2103050A1 (en) 1992-11-16
AU673803B2 (en) 1996-11-28
IE921581A1 (en) 1992-11-18
EP0586523A1 (en) 1994-03-16
NO934059D0 (no) 1993-11-09
US5728684A (en) 1998-03-17
EP0586523A4 (en) 1995-11-29
IL101879A0 (en) 1992-12-30
IL101879A (en) 1998-06-15
HU9303237D0 (en) 1994-03-28
NO308884B1 (no) 2000-11-13
AU1998292A (en) 1992-12-30
KR100245252B1 (ko) 2000-03-02
JPH06507902A (ja) 1994-09-08
NO306850B1 (no) 2000-01-03
NO992273L (no) 1999-05-11
NO992273D0 (no) 1999-05-11

Similar Documents

Publication Publication Date Title
BG98217A (bg) Определяне на предшественици,метаболизиращи се вчерния дроб до биологично активни продукти и терапевтичното им приложение
RU2099338C1 (ru) (-)-энантиомер цис-4-амино-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1н)-пиримидин-2-она или его соль, или его сложный эфир, или соль его сложного эфира, смесь (-)-энантиомера и (+)-энантиомера, способы их получения, антивирусная композиция и способ лечения млекопитающих, включая человека, страдающих от вирусной инфекции или восприимчивых к ней
US6815542B2 (en) Nucleoside compounds and uses thereof
CN1257912C (zh) 用于治疗乙型肝炎的β－L－2′－脱氧－核苷
JP5357857B2 (ja) 抗ガン剤及びｄｎａ複製阻害剤
US20030125298A1 (en) Cancer therapy comprising deaminase enzyme inhibitors
US20030008841A1 (en) Anti-HCV nucleoside derivatives
JP2003201240A (ja) アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法
US4880918A (en) Arrest and killing of tumor cells by adenosine 5-diphosphate and adenosine-5-triphosphate
SK119993A3 (en) Antiviral combinations
HU228064B1 (en) New antiviral nucleoside derivatives
CN102939279A (zh) 苯基硫代乙酸酯/盐化合物、组合物及其使用方法
JPH06508846A (ja) アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療
US6645972B2 (en) Methods of treating leukemia
AU2002336864A1 (en) Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
US5763419A (en) Treatment of malignant tumors with 8-chloroadenosine 3',5'-cyclic monophasphate
TW200425895A (en) Compositions and methods for combination antiviral therapy
KR101323698B1 (ko) Ａｚｔ의 변형된 5'-포스포네이트 - 잠재적 항바이러스제
US20040192652A1 (en) Pharmaceutical combinations and methods for the treatment of leukemia
JPS6337767B2 (no)
JP4395901B2 (ja) 新規遺伝子治療用薬剤
IL121375A (en) Preparation of compositions of prodrugs metabolizable by the liver
JPH0145450B2 (no)
JPS6345372B2 (no)